Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hsp90

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Hsp90. Displaying page 1 of 1.
    EudraCT Number: 2009-014796-51 Sponsor Protocol Number: 120BC201 Start Date*: 2010-02-02
    Sponsor Name:Biogen Idec Ltd.
    Full Title: Phase 2a, open-label, randomized, noncomparative study of BIIB021 in combination with exemestane in women with hormone receptor-positive, advanced metatatic breast cancer who have progressed on a n...
    Medical condition: Advanced Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021444-18 Sponsor Protocol Number: SPON845-10 Start Date*: 2010-10-18
    Sponsor Name:Cardiff University
    Full Title: TO ESTABLISH THE FEASIBILITY OF COMBINING EITHER THE TYROSINE KINASE INHIBITOR AC220 OR THE CXCR4 INHIBITOR PLERIXAFOR OR THE HSP90 INHIBITOR, GANETESPIB, WITH CHEMOTHERAPY IN OLDER PATIENTS WITH A...
    Medical condition: Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003868-31 Sponsor Protocol Number: GANNET53 Start Date*: 2014-04-22
    Sponsor Name:Medizinische Universität Innsbruck, AGO Studienzentrale
    Full Title: A two-part, multicentre, international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with high-grade serous...
    Medical condition: platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer with mutant p53
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004058-40 Sponsor Protocol Number: EUDARIO Start Date*: 2018-10-16
    Sponsor Name:Katholieke Universiteit Leuven
    Full Title: A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment ...
    Medical condition: Platinum-sensitive relapsed ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002766-20 Sponsor Protocol Number: CAUY922A2101 Start Date*: 2009-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in...
    Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016027-62 Sponsor Protocol Number: GEIS-21 Start Date*: 2010-02-11
    Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACION EN SARCOMAS
    Full Title: ENSAYO CLÍNICO, FASE II, ABIERTO, NO CONTROLADO, MULTICÉNTRICO Y PROSPECTIVO, DE QUIMIOTERAPIA INTENSIVA, CIRUGÍA Y RADIOTERAPIA EN SARCOMA DE EWING DE NIÑOS Y ADULTOS JÓVENES
    Medical condition: Pacientes niños y adultos jóvenes con sarcoma de Ewing
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005533-39 Sponsor Protocol Number: Debio0932-201 Start Date*: 2012-02-27
    Sponsor Name:Debiopharm International SA
    Full Title: A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with standard of care in first- and second-line therapy of patients with Stage IIIb or IV No...
    Medical condition: Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10025054 Lung cancer non-small cell stage IIIB LLT
    16.1 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001574-28 Sponsor Protocol Number: AT13387-04 Start Date*: 2012-10-09
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Phase 2 Study of Hsp90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
    Medical condition: Castration-Resistant Prostate Cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-006279-35 Sponsor Protocol Number: CAUY922A2103 Start Date*: 2008-09-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, Phase I-Ib/II study of AUY922 administered as single agent and in combination with bortezomib with or without dexamethasone in adult patients with relapsed or refractor...
    Medical condition: adult patients with relapsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001575-37 Sponsor Protocol Number: AT13387-05 Start Date*: 2014-12-15
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC).
    Medical condition: Non-small cell lung cancer (NSCLC) which represents 85% of all lung cancers.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015407-47 Sponsor Protocol Number: CAUY922A2202 Start Date*: 2010-10-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy
    Medical condition: Patients with advanced gastric cancer who have progressed after one line of chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015628-27 Sponsor Protocol Number: CAUY922A2109 Start Date*: 2010-08-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that ha...
    Medical condition: locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020116-11 Sponsor Protocol Number: CAUY922A2206 Start Date*: 2010-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior che...
    Medical condition: patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002570-23 Sponsor Protocol Number: CAUY922A2205 Start Date*: 2011-12-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-...
    Medical condition: Patients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER-2 positive gastric cancer LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:53:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA